Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 809Neoplasms, Plasma Cell 111Recurrence 109Immunoglobulin Light-chain Amyloidosis 50Neoplasms 33Amyloidosis 21Smoldering Multiple Myeloma 15Renal Insufficiency 13Paraproteinemias 12Lymphoma, Non-Hodgkin 12Hematologic Diseases 11Leukemia, Plasma Cell 10Lymphoma 9Plasmacytoma 8Leukemia, Myeloid, Acute 7Hematologic Neoplasms 7Disease 6Blood Protein Disorders 6Lymphoma, Large B-Cell, Diffuse 5Leukemia, Lymphocytic, Chronic, B-Cell 5Leukemia 5Hodgkin Disease 5Neoplasm, Residual 4Nausea 4Myelodysplastic Syndromes 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Disease Progression 4Chromosome 17 deletion 4

Interventions

Dexamethasone 4selinexor 1pomalidomide 1ixazomib 1birtamimab 1Positron-Emission Tomography 1Melphalan 1Cyclophosphamide 1Calcium Dobesilate 1Bortezomib 1Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Alzheimer Disease × Dexamethasone × Plasma cell × Clear all
NCT04270175 2026-02-27

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Weill Medical College of Cornell University

Phase 2 Active not recruiting
15 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease

NCT04984330 2022-11-17

STARR

Weill Medical College of Cornell University

Phase EARLY_PHASE1 Withdrawn
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease, Amyloidosis

NCT03236792 2022-09-29

Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
28 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease

NCT01083316 2020-09-25

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Boston Medical Center

Phase 2 Completed
35 enrolled 9 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡